Semi-Annual Shareholder Report

June 30, 2023

Share Class

Primary

Federated Hermes Kaufmann Fund II

Service

A Portfolio of Federated Hermes Insurance Series

Dear Valued Shareholder,

We are pleased to present the Semi-Annual Shareholder Report for your fund covering the period from January 1, 2023 through June 30, 2023. This report includes a complete listing of your fund's holdings, performance information and financial statements along with other important fund information.

Federated

Hermes

As a global leader in active, responsible investment management, Federated Hermes is guided by our conviction that responsible investing is the best way to create wealth over the long term. The company provides capabilities across a wide range of asset classes to investors around the world.

In addition, <u>FederatedHermes.com/us</u> offers quick and easy access to valuable resources that include timely fund updates, economic and market insights from our investment strategists and financial planning tools. You can also access many of those insights by following us on Twitter (@FederatedHermes) and LinkedIn.

Thank you for investing with us. We hope you find this information useful and look forward to keeping you informed. Sincerely,

John B. Fisher, President

CONTENTS

Portfolio of Investments Summary Table	1
Portfolio of Investments	2
Financial Highlights	9
Statement of Assets and Liabilities	11
Statement of Operations	12
Statement of Changes in Net Assets	
Notes to Financial Statements	14
Shareholder Expense Example	20
Evaluation and Approval of Advisory Contract	21
Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness	26
Voting Proxies on Fund Portfolio Securities	27
Quarterly Portfolio Schedule	27

Portfolio of Investments Summary Table (unaudited)

At June 30, 2023, the Fund's sector composition¹ was as follows:

Sector Composition	Percentage of Total Net Assets
Health Care	39.1%
Consumer Discretionary	9.9%
Industrials	8.4%
Financials	7.6%
Materials	7.1%
Real Estate	7.0%
Information Technology	6.0%
Consumer Staples	2.9%
Utilities	2.5%
Energy	2.1%
Communication Services	0.9%
U.S. Treasury Notes	2.7%
Securities Lending Collateral ²	1.3%
Cash Equivalents ³	3.8%
Other Assets and Liabilities—Net ⁴	(1.3)%
TOTAL	100%

1 Except for Securities Lending Collateral, Cash Equivalents and Other Assets and Liabilities, sector classifications are based upon, and individual portfolio securities are assigned to, the classifications of the Global Industry Classification Standard (GICS), except that the Adviser assigns a classification to securities not classified by the GICS and to securities for which the Adviser does not have access to the classification made by the GICS.

2 Represents cash collateral received for portfolio securities on loan that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements.

3 Cash Equivalents include any investments in money market mutual funds and/or overnight repurchase agreements other than those representing securities lending collateral.

4 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Portfolio of Investments

June 30, 2023 (unaudited)

hares or Principal Amount		Value
	COMMON STOCKS—91.6%	
	Communication Services—0.9%	
1,160	¹ Alphabet, Inc., Class A	\$ 138,852
12,000	Infrastrutture Wireless Italiane SPA	158,44
3,100	¹ Pinterest, Inc.	84,75
1,000	¹ Take-Two Interactive Software, Inc.	147,160
27,700	Universal Music Group	615,42
5,300	¹ ZoomInfo Technologies, Inc.	134,565
	TOTAL	1,279,203
	Consumer Discretionary—9.5%	
3,489	¹ Airbnb, Inc.	447,150
13,150	¹ Alibaba Group Holding Ltd., ADR	1,096,053
9,392	¹ Amazon.com, Inc.	1,224,34
9,154	¹ Bowlero Corp.	106,553
466	¹ Chipotle Mexican Grill, Inc.	996,774
4,569	Choice Hotels International, Inc.	536,94
1,500	¹ Etsy, Inc.	126,91
2,230	¹ Five Below, Inc.	438,284
5,476	¹ Floor & Decor Holdings, Inc.	
22,900	¹ Las Vegas Sands Corp.	1,328,200
2,200	¹ Lululemon Athletica, Inc.	832,700
2,200	¹ Mercadolibre, Inc.	355,380
	Morcladollore, Inc.	
9,630		666,333
690,074	NagaCorp Ltd.	365,313
2,912	Nike, Inc., Class B	321,398
11,760	¹ Planet Fitness, Inc.	793,094
57,156	¹ Sportradar Group AG	737,312
601	Vail Resorts, Inc.	151,30
13,300	Wingstop, Inc.	2,662,128
	TOTAL	13,755,470
	Consumer Staples—2.9%	
1,495	Costco Wholesale Corp.	
17,000	¹ Kenvue, Inc.	449,140
29,300	Philip Morris International, Inc.	2,860,266
	TOTAL	4,114,284
	Energy—2.1%	
9,250	Cheniere Energy, Inc.	1,409,330
59,400	New Fortress Energy, Inc.	1,590,732
	TOTAL	3,000,062
	Financials—7.5%	
22,200	Apollo Global Management, Inc.	1,705,182
1,740	BlackRock, Inc.	1,202,584
201,000	¹ Blue Owl Capital, Inc.	2,341,650
62,400	FinecoBank Banca Fineco SPA	841,70
20,700	Hamilton Lane Alliance Holdings I, Inc.	1,655,586
10,401	London Stock Exchange Group PLC	1,102,15
1,755	MSCI, Inc., Class A	823,60
2,938	S&P Global, Inc.	1,177,81
2,,00	TOTAL	10,850,288

rincipal		
mount		Value
	COMMON STOCKS—continued Health Care—38.4%	
32,204	189Bio, Inc.	\$ 610
	Abbott Laboratories	359
3,300		
8,594	¹ Acrivon Therapeutics, Inc.	111
58,700	1.2Albireo Pharma, Inc.	126
33,480	¹ Amphastar Pharmaceuticals, Inc.	1,924
22,901	¹ Amylyx Pharmaceuticals, Inc.	493
57,800	¹ Annexon, Inc.	203
73,500	¹ Arcturus Therapeutics Holdings, Inc.	2,107
18,750	¹ Argenx SE	7,294
1,900	AstraZeneca PLC	272
40,966	¹ aTyr Pharma, Inc.	304
7,369	¹ Century Therapeutics, Inc.	23
10,433	¹ Cerevel Therapeutics Holdings	331
15,546	¹ Chinook Therapeutics, Inc.	597
56,475	^{1,2} Contra Akouos, Inc., Rights	44
79,226	¹ Corcept Therapeutics, Inc.	1,762
5,758	¹ CRISPR Therapeutics AG	323
12,809	Danaher Corp.	3,074
12,000	¹ Denali Therapeutics, Inc.	354
34,900	¹ Dexcom, Inc.	4,484
94,638	¹ Dynavax Technologies Corp.	2,514
14,135	¹ EDAP TMS SA, ADR	130
4,400	Eli Lilly & Co.	2,063
1,500	¹ Establishment Labs Holdings, Inc.	102
14,100	¹ Fusion Pharmaceuticals, Inc.	65
39,400	¹ Fusion Pharmaceuticals, Inc.	184
04,689	¹ Fusion Pharmaceuticals, Inc.	489
1,925	¹ Genmab A/S	730
13,800	¹ Guardant Health, Inc.	494
43,800	¹ IDEAYA Biosciences, Inc.	1,029
1,175	¹ IDEXX Laboratories, Inc.	590
1,665	¹ Illumina, Inc.	312
3,746	¹ Inspire Medical Systems, Inc.	1,216
3,347	¹ Insulet Corp.	965
29,338	Intellia Therapeutics, Inc.	1,196
2,300	¹ Intuitive Surgical, Inc.	786
800	Lantheus Holdings, Inc.	67
4,307	^{1,2} Laronde, Inc.	93
27,416	¹ Legend Biotech Corp., ADR	1,892
23,700	¹ Merus N.V.	624
17,225	¹ Minerva Neurosciences, Inc.	157
4,050	^{1,2} Minerva Neurosciences, Inc.	29
4,030 17,548	¹ Moonlake Immunotherapeutics	894
8,700	¹ Morphic Holding, Inc.	498
6,763	¹ Natera, Inc.	329
5,400	Novo Nordisk A/S	872
12,041	¹ Orchard Therapeutics PLC, ADR	62
250	¹ Penumbra, Inc.	86
6,500	¹ Privia Health Group, Inc. ¹ Regulus Therapeutics, Inc.	169 51

nount		Valu
	COMMON STOCKS—continued	
	Health Care—continued	
5,752	¹ Regulus Therapeutics, Inc.	\$ 23
5,350	¹ Repligen Corp.	756
34,174	¹ Rezolute, Inc.	166
52,844	¹ Rhythm Pharmaceuticals, Inc.	1,036
4,700	¹ Sarepta Therapeutics, Inc.	1,683
0,914	¹ Scynexis, Inc.	120
4,801	¹ Seres Therapeutics, Inc.	1,555
4,700	¹ Structure Therapeutics, Inc., ADR	61
1,750	Stryker Corp.	533
5,300	¹ Tela Bio, Inc.	154
26,600	¹ Ultragenyx Pharmaceutical, Inc.	1,227
1,487	UnitedHealth Group, Inc.	714
1,450	¹ Vaxcyte, Inc.	72
6,400	¹ Veeva Systems, Inc.	1,265
25,698	¹ Verona Pharma PLC, ADR	543
36,640	¹ Verve Therapeutics, Inc.	68
29,241	¹ Zentalis Pharmaceuticals, LLC	824
	TOTAL	55,483
	Industrials—8.1%	
8,500	ABB Ltd.	72
2,250	Comfort Systems USA, Inc.	369
7,474	Eaton Corp. PLC	1,503
2,000	¹ Generac Holdings, Inc.	29
6,000	¹ GXO Logistics, Inc.	370
0,378	HEICO Corp.	1,830
3,600	Quanta Services, Inc.	2,67
1,036	Rockwell Automation, Inc.	34
7,900	Trane Technologies PLC	1,510
2,006	Wabtec Corp.	1,310
6,326	Xylem, Inc.	71:
	TOTAL	11,664
	Information Technology—5.7%	
1,000	¹ Adobe, Inc.	488
400	¹ Advanced Micro Devices, Inc.	4!
2,721	¹ Confluent, Inc.	90
2,200	¹ Crowdstrike Holdings, Inc.	323
7,400	¹ HashiCorp, Inc.	455
200	¹ Keysight Technologies, Inc.	33
700	Marvell Technology, Inc.	4
450	Microsoft Corp.	15.
6,574	¹ Okta, Inc.	455
2,100	¹ Palo Alto Networks, Inc.	530
5,800	¹ Q2 Holdings, Inc.	179
3,466	¹ Rogers Corp.	56
2,750	¹ ServiceNow, Inc.	33
8,000	¹ Shopify, Inc.	1,162
4,900	¹ Splunk, Inc.	51
1,500	Taiwan Semiconductor Manufacturing Co. Ltd., ADR	15
2,457	¹ Tyler Technologies, Inc.	1,02

Shares or Principal		
Amount	COMMON STOCKS—continued	Value
	Information Technology—continued	
2,233	¹ Workday, Inc.	\$ 504,412
2,233	TOTAL	8,277,923
	Materials—7.1%	0,277,723
58,712	Agnico Eagle Mines Ltd.	2,934,426
3,250	Albemarle Corp.	725,042
118,100	Barrick Gold Corp.	1,999,433
59,200	Newmont Corp.	2,525,472
5,930	Sherwin-Williams Co.	1,574,534
4,434	Westlake Corp.	529,730
.,	TOTAL	10,288,637
	Real Estate—6.9%	
33,800	Americold Realty Trust, Inc.	1,091,740
33,273	¹ CoStar Group, Inc.	2,961,297
9,650	Crown Castle International Corp.	1,099,521
17,796	Easterly Government Properties, Inc.	258,042
5,800	Gaming and Leisure Properties, Inc.	281,068
5,453	National Storage Affiliates Trust	189,928
54,177	Physicians Realty Trust	757,936
8,800	ProLogis, Inc.	1,079,144
5,373	Ryman Hospitality Properties, Inc.	499,259
10,200	STAG Industrial, Inc.	365,976
44,400	VICI Properties, Inc.	1,395,492
	TOTAL	9,979,403
	Utilities—2.5%	
7,300	American Electric Power Co., Inc.	614,660
11,400	Duke Energy Corp.	1,023,036
25,800	NextEra Energy, Inc.	1,914,360
	TOTAL	3,552,056
	TOTAL COMMON STOCKS (IDENTIFIED COST \$88,907,405)	132,246,260
	U.S. TREASURIES—2.7%	
	U.S. Treasury Notes—2.7%	
\$3,500,000	United States Treasury Note, 4.125%, 11/15/2032	3,575,790
300,000	United States Treasury Note, 4.375%, 10/31/2024	296,391
	TOTAL U.S. TREASURIES (IDENTIFIED COST \$3,888,033)	3,872,181
	CORPORATE BONDS—0.9%	
	Consumer Discretionary—0.4%	
147,000	Airbnb, Inc., Conv. Bond, 0.010%, 3/15/2026	129,430
65,000	Chegg, Inc., Conv. Bond, 0.125%, 3/15/2025	57,266
200,000	Mercadolibre, Inc., Sr. Unsecd. Note, 2.375%, 1/14/2026	181,288
200,000	NagaCorp Ltd., Sr. Unsecd. Note, 7.950%, 7/6/2024	188,790
	TOTAL	556,774
	Health Care—0.1%	
151,000	Illumina, Inc., Conv. Bond, 0.010%, 8/15/2023	149,423
	Industrials—0.1%	
86,000	Fiverr International Ltd., Conv. Bond, 0.000%, 11/1/2025	72,716
	Information Technology—0.3%	
145,000	DocuSign, Inc., Conv. Bond, 0.010%, 1/15/2024	140,533
145,000	Okta, Inc., Conv. Bond, 0.125%, 9/1/2025	132,380
95,000	RingCentral, Inc., Conv. Bond, 6.220%, 3/1/2025	

Shares or Principal Amount			Value
	CORPORATE BONDS—continued		
	Information Technology—continued		
\$ 145,000	Shopify, Inc., Conv. Bond, 0.125%, 11/1/2025	\$	131,791
	TOTAL		492,224
	TOTAL CORPORATE BONDS (IDENTIFIED COST \$1,248,154)		1,271,137
	PREFERRED STOCKS—0.8%		
	Financials—0.1%		
2,715	JPMorgan Chase & Co., 5.750%, 12/31/2049		68,255
2,890	Wells Fargo & Co., 5.625%, 12/31/2049	-	66,817
	TOTAL		135,072
	Health Care—0.4%		
53,840	² CeQur SA		307,246
32,229	Regulus Therapeutics, Inc.	-	47,377
1,382	Regulus Therapeutics, Inc.	-	203,154
	TOTAL		557,777
	Industrials—0.2%		
12,000	FTAI Aviation Ltd., 12/31/2049		283,800
	Real Estate—0.1%		
3,100	Public Storage, 4.000%, 12/31/2049		58,745
2,700	Public Storage, 4.625%, 12/31/2049	-	59,481
2,500	Rexford Industrial Realty, Inc., 5.875%, 12/31/2049	-	57,100
_,	TOTAL		175,326
	Utilities_0.0%		., 0,020
1,500	NextEra Energy, Inc., 6.219%, 9/1/2023		73,545
1,000	TOTAL PREFERRED STOCKS (IDENTIFIED COST \$1,210,312)		1,225,520
	¹ WARRANTS-0.2%		.,,
	Health Care—0.2%		
11,450	Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 2/8/2024		36
5,250	² Minerva Neurosciences, Inc., Warrants, Expiration Date 12/31/2099	-	38,451
5,230	Rezolute, Inc., Warrants, Expiration Date 10/8/2027	-	3,116
1,400	Rezolute, Inc., Warrants, Expiration Date 1/1/2099	-	2,772
44,952	Rezolute, Inc., Warrants, Expiration Date 1/1/2099 Rezolute, Inc., Warrants, Expiration Date 12/31/2099	-	89,005
26,500		-	8,859
	Scynexis, Inc., Warrants, Expiration Date 5/21/2024	-	
644	Scynexis, Inc., Warrants, Expiration Date 4/26/2029	-	1,454
53,000	Scynexis, Inc., Warrants, Expiration Date 1/1/2099 TOTAL WARRANTS		156,350
	(IDENTIFIED COST \$563,503)		300,043
\$5,533,000	REPURCHASE AGREEMENTS—5.1% Interest in \$1,976,000,000 joint repurchase agreement 5.06%, dated 6/30/2023 under which Bank of America, N.A. will repurchase securities provided as collateral for \$1,976,833,213 on 7/3/2023. The securities provided as collateral at the end of the period held with BNY Mellon as tri-party agent, were U.S. Government Agency securities with various maturities to		
1,877,119	7/20/2052 and the market value of those underlying securities was \$2,016,369,878. Interest in \$1,976,000,000 joint repurchase agreement 5.06%, dated 6/30/2023 under which Bank of America, N.A. will repurchase securities provided as collateral for \$1,976,833,213 on 7/3/2023. The securities provided as collateral at the end of the period held with BNY Mellon as tri-party agent, were U.S. Government Agency securities with various maturities to 7/20/2052 and the market value of those underlying securities was \$2,016,369,878 (purchased with proceeds from securities lending collateral).	-	5,533,000
	TOTAL REPURCHASE AGREEMENTS (IDENTIFIED COST \$7,410,119)		7,410,119
	TOTAL INVESTMENT IN SECURITIES—101.3% (IDENTIFIED COST \$103,227,526) ³	14	46,325,260
	OTHER ASSETS AND LIABILITIES - NET—(1.3)% ⁴		(1,878,040)
	TOTAL NET ASSETS—100%	\$14	44,447,220

An affiliated company is a company in which the Fund, alone or in combination with other funds, has ownership of at least 5% of the voting shares. Transactions with the affiliated companies during the period ended June 30, 2023, were as follows:

Affiliated		alue as of 2/31/2022		urchases at Cost*		Proceeds om Sales*	U Ap	Change in Inrealized preciation/ preciation*		Net ized Gain/ (Loss)*		alue as of /30/2023	Shares Held as of 6/30/2023	
Health Care:	\$	70/ 00/	¢		¢/	2 E01 (0E)	¢	2/1 270	¢	E0 700	¢	10/ 205	E0 700	\$
Albireo Pharma, Inc.**						2,591,605)	\$	261,379	\$		\$	126,205	58,700	
Amphastar Pharmaceuticals, Inc.	\$	938,110		_			\$	985,986	\$			1,924,096	33,480	<u>\$</u>
Annexon, Inc.	\$	298,826				_	\$	(95,370)	\$	_	\$	203,456	57,800	\$
Arcturus Therapeutics Holdings, Inc.		1,106,284				_	\$	856,976	\$	—		2,107,980	73,500	\$
aTyr Pharma, Inc.	\$			167,324	-	_	\$	(8,691)	\$	_	\$	304,487	140,966	\$
Dynavax Technologies Corp.	-	2,070,948				_	\$	443,775	\$	_		2,514,723	194,638	\$—
Fusion Pharmaceuticals, Inc.	\$	44,415	\$	_	\$	_	\$	21,573	\$	—	\$	65,988	14,100	\$—
Fusion Pharmaceuticals, Inc.	\$	_	\$	133,960	\$	_	\$	50,432	\$	_	\$	184,392	39,400	\$—
Fusion Pharmaceuticals, Inc.	\$	_	\$	437,600	\$	_	\$	52,345	\$	_	\$	489,945	104,689	\$—
IDEAYA Biosciences, Inc.	\$	657,754	\$	140,600	\$	_	\$	230,946	\$	_	\$	1,029,300	43,800	\$—
Merus N.V.	\$	762,594	\$	_	\$	(423,598)	\$	398,738	\$(113,713)	\$	624,021	23,700	\$—
Minerva Neurosciences, Inc.	\$	27,388	\$	_	\$	_	\$	130,048	\$	_	\$	157,436	17,225	\$—
Minerva Neurosciences, Inc.	\$	_	\$	40,500	\$	(21,676)	\$	10,838	\$	_	\$	29,662	4,050	\$—
Minerva Neurosciences, Inc., Warrants, Expiration Date 12/31/2099	\$	_	\$	52,447	ŝ		\$	(13,996)	\$		\$	38,451	5,250	\$
Orchard Therapeutics PLC, ADR**	\$	72,679		50,966		_	\$	227,917		289,069)	\$	62,493	12,041	
Regulus Therapeutics, Inc.	\$	44,154				_	\$	3,223	\$		\$	47,377	32,229	\$
Regulus Therapeutics, Inc.	\$	48,397	_		-		\$	3,532	\$		\$	51,929	35,326	
	¢ \$			124,394		_	¢ \$	78,760	ډ \$	_	¢ \$			 \$
Regulus Therapeutics, Inc.												203,154	1,382	
Regulus Therapeutics, Inc.	\$			14,178	_	_	\$	8,977	\$	_	\$	23,155	15,752	\$
Rezolute, Inc.	\$	174,240	\$	_	\$		\$	(7,575)	\$		\$	166,665	84,174	\$—
Rezolute, Inc., Warrants, Expiration Date 10/8/2027	\$	3,452	\$	_	\$	_	\$	(336)	\$	_	\$	3,116	5,696	\$—
Rezolute, Inc., Warrants, Expiration Date 1/1/2099	\$	2,898	\$	_	\$	_	\$	(126)	\$	_	\$	2,772	1,400	\$—
Rezolute, Inc., Warrants, Expiration Date 12/31/2099	\$	93,051	\$	_	\$	_	\$	(4,046)	\$	_	\$	89,005	44,952	\$
Rhythm Pharmaceuticals, Inc.	\$	3,316,768		_	\$(1,426,995)	\$(1,568,989)	\$	715,514	\$	1,036,298	62,844	\$
Scynexis, Inc.	\$	63,826		_			\$	56,870	\$	_	\$	120,696	40,914	\$
Scynexis, Inc., Warrants, Expiration Date 5/21/2024	\$			_		_	\$	7,659	\$	_	\$	8,859	26,500	 \$
Scynexis, Inc., Warrants, Expiration Date 4/26/2029	\$	570		_		_	\$	884	\$	_	\$	1,454	644	 \$
Scynexis, Inc., Warrants, Expiration Date 1/1/2099	\$	82,680		_	\$	_	\$	73,670	\$	_	\$	156,350	53,000	\$—
Seres Therapeutics, Inc.		1,978,480				(235,866)				(85,126)		1,555,797	324,801	\$—
Affiliated Issuers no longer in the portfolio at period end		2,517,857				1,989,484)	\$			966,981)	\$		_	\$—
TOTAL OF AFFILIATED COMPANIES TRANSACTIONS	\$	15,159,331	\$3	3,078,986	\$(6,689,224)	\$	2,460,844	\$(680,675)	\$`	13,329,262	1,552,953	\$—

* A portion of the amount shown was recorded when the Fund no longer had ownership of at least 5% of the voting shares.

** At June 30, 2023, the Fund no longer has ownership of at least 5% of the voting shares.

1 Non-income-producing security.

2 Market quotations and price valuations are not available. Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Fund's Adviser acting through its Valuation Committee.

3 The cost of investments for federal tax purposes amounts to \$103,227,745.

4 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Note: The categories of investments are shown as a percentage of total net assets at June 30, 2023.

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—quoted prices in active markets for identical securities.

Level 2—other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Also includes securities valued at amortized cost.

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used, as of June 30, 2023, in valuing the Fund's assets carried at fair value:

Valuation Inputs

	Level 1— Quoted Prices	Level 2— Other Significant Observable Inputs	Level 3— Significant Unobservable Inputs	Total
Equity Securities:				
Common Stocks				
Domestic	\$101,958,942	\$ —	\$293,880	\$102,252,822
International	16,346,185	13,647,253	_	29,993,438
Preferred Stocks				
Domestic	634,474	_	_	634,474
International	283,800	_	307,246	591,046
Debt Securities:				
U.S. Treasuries	_	3,872,181	_	3,872,181
Corporate Bonds	_	1,271,137	_	1,271,137
Warrants	91,777	169,815	38,451	300,043
Repurchase Agreements	_	7,410,119	_	7,410,119
TOTAL SECURITIES	\$119,315,178	\$26,370,505	\$639,577	\$146,325,260

The following acronym(s) are used throughout this portfolio:

ADR—American Depositary Receipt

Financial Highlights – Primary Shares

(For a Share Outstanding Throughout Each Period)

	Six Months Ended (unaudited)		Year Ended December 31,							
	6/30/2023	2022	2021	2020	2019	2018				
Net Asset Value, Beginning of Period	\$15.10	\$24.31	\$25.46	\$22.63	\$18.55	\$19.16				
Income From Investment Operations:										
Net investment income (loss) ¹	0.02	(0.08)	(0.24)	(0.22)	(0.10)	(0.11)				
Net realized and unrealized gain (loss)	1.16	(6.87)	0.83	5.27	6.15	0.95				
TOTAL FROM INVESTMENT OPERATIONS	1.18	(6.95)	0.59	5.05	6.05	0.84				
Less Distributions:										
Distributions from net realized gain	_	(2.26)	(1.74)	(2.22)	(1.97)	(1.45)				
Net Asset Value, End of Period	\$16.28	\$15.10	\$24.31	\$25.46	\$22.63	\$18.55				
Total Return ²	7.81%	(30.09)%	2.51%	28.79%	33.82%	3.84%				

Ratios to Average Net Assets:

Net expenses ³	1.54% ⁴	1.54%	1.50%	1.50%	1.51%	1.52%
Net investment income (loss)	0.29%4	(0.51)%	(0.99)%	(1.01)%	(0.49)%	(0.53)%
Expense waiver/reimbursement ⁵	<u> %</u> 4	0.00%6	—%	—%	—%	_%
Supplemental Data:						
Net assets, end of period (000 omitted)	\$33,968	\$34,430	\$55,366	\$63,502	\$57,988	\$46,160
Portfolio turnover ⁷	24%	41%	34%	45%	43%	41%

1 Per share numbers have been calculated using the average shares method.

2 Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract. Total returns for periods of less than one year are not annualized.

3 Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

4 Computed on an annualized basis.

5 This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/ reimbursement recorded by investment companies in which the Fund may invest.

6 Represents less than 0.01%.

7 Securities that mature are considered sales for purposes of this calculation.

Financial Highlights - Service Shares

(For a Share Outstanding Throughout Each Period)

	Six Months Ended		Year	nded Decembe	er 31.	
	(unaudited)	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$13.73	\$22.40	\$23.65	\$21.27	\$17.57	\$18.26
Income From Investment Operations:						
Net investment income (loss) ¹	0.00 ²	(0.11)	(0.28)	(0.26)	(0.15)	(0.15)
Net realized and unrealized gain (loss)	1.05	(6.30)	0.77	4.86	5.82	0.91
TOTAL FROM INVESTMENT OPERATIONS	1.05	(6.41)	0.49	4.60	5.67	0.76
Less Distributions:						
Distributions from net realized gain	_	(2.26)	(1.74)	(2.22)	(1.97)	(1.45)
Net Asset Value, End of Period	\$14.78	\$13.73	\$22.40	\$23.65	\$21.27	\$17.57
Total Return ³	7.65%	(30.26)%	2.26%	28.48%	33.52%	3.58%

Ratios to Average Net Assets:

1.79% ⁵	1.79%	1.75%	1.75%	1.76%	1.77%
0.04% ⁵	(0.73)%	(1.24)%	(1.26)%	(0.74)%	(0.77)%
—% ⁵	0.00%7	—%	—%	—%	_%
\$110,480	\$108,981	\$150,983	\$169,061	\$129,327	\$105,132
24%	41%	34%	45%	43%	41%
	0.04% ⁵ —% ⁵ \$110,480	0.04% ⁵ (0.73)% <u>-%⁵</u> 0.00% ⁷ \$110,480 \$108,981	0.04% ⁵ (0.73)% (1.24)% -% ⁵ 0.00% ⁷ -% \$110,480 \$108,981 \$150,983	0.04% ⁵ (0.73)% (1.24)% (1.26)% -% ⁵ 0.00% ⁷ -% -% \$110,480 \$108,981 \$150,983 \$169,061	0.04% ⁵ (0.73)% (1.24)% (1.26)% (0.74)% -% ⁵ 0.00% ⁷ -% -% -% \$110,480 \$108,981 \$150,983 \$169,061 \$129,327

1 Per share numbers have been calculated using the average shares method.

2 Represents less than \$0.01.

3 Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract. Total returns for periods of less than one year are not annualized.

4 Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

5 Computed on an annualized basis.

6 This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/ reimbursement recorded by investment companies in which the Fund may invest.

7 Represents less than 0.01%.

8 Securities that mature are considered sales for purposes of this calculation.

Statement of Assets and Liabilities

June 30, 2023 (unaudited)

Assets:

Investment in securities, at value including \$1,846,074 of securities loaned and \$13,140,564 of investments in affiliated holdings*	' (identified
cost \$103,227,526, including \$13,398,147 of identified cost in affiliated holdings)	\$146,325,260
Cash	771
Income receivable	122,505
Receivable for investments sold	103,811
Receivable for shares sold	64,609
TOTAL ASSETS	146,616,956
Liabilities:	
Payable for investments purchased	172,875
Payable for shares redeemed	36,845
Payable for collateral due to broker for securities lending (Note 2)	1,877,119
Payable for investment adviser fee (Note 5)	5,094
Payable for administrative fee (Note 5)	305
Payable for distribution services fee (Note 5)	22,449
Accrued expenses (Note 5)	55,049
TOTAL LIABILITIES	2,169,736
Net assets for 9,561,717 shares outstanding	\$144,447,220
Net Assets Consist of:	
Paid-in capital	\$ 99,164,461
Total distributable earnings (loss)	45,282,759
TOTAL NET ASSETS	\$144,447,220
Net Asset Value, Offering Price and Redemption Proceeds Per Share:	
Primary Shares:	
\$33,967,673 ÷ 2,086,462 shares outstanding, no par value, unlimited shares authorized	\$16.28
Service Shares:	
\$110,479,547 ÷ 7,475,255 shares outstanding, no par value, unlimited shares authorized	\$14.78

* See information listed after the Fund's Portfolio of Investments.

Statement of Operations

Six Months Ended June 30, 2023 (unaudited)

Investment Income:	
Dividends	\$ 846,103
Interest	438,503
Net income on securities loaned (Note 2)	11,387
TOTAL INCOME	1,295,993
Expenses:	
Investment adviser fee (Note 5)	923,523
Administrative fee (Note 5)	56,628
Custodian fees	10,488
Transfer agent fees	7,177
Directors'/Trustees' fees (Note 5)	966
Auditing fees	18,000
Legal fees	6,271
Portfolio accounting fees	32,095
Distribution services fee (Note 5)	135,280
Printing and postage	17,115
Miscellaneous (Note 5)	20,293
TOTAL EXPENSES	1,227,836
Net investment income	68,157
Realized and Unrealized Gain (Loss) on Investments and Foreign Currency Transactions:	
Net realized gain on investments (including net realized loss of \$(450,306) on sales of investments in affiliated holdings*)	3,283,816
Net realized loss on foreign currency transactions	(535)
Net change in unrealized appreciation of investments (including net change in unrealized depreciation of \$1,453,258 of investments in affiliated holdings*)	7,311,550
Net change in unrealized appreciation/depreciation of translation of assets and liabilities in foreign currency	39
Net realized and unrealized gain (loss) on investments and foreign currency transactions	10,594,870
Change in net assets resulting from operations	\$10,663,027

* See information listed after the Fund's Portfolio of Investments.

Statement of Changes in Net Assets

	Six Months Ended (unaudited) 6/30/2023	Year Ended 12/31/2022
Increase (Decrease) in Net Assets		
Operations:		
Net investment income (loss)	\$ 68,157	\$ (1,052,951)
Net realized gain (loss)	3,283,281	(662,474)
Net change in unrealized appreciation/depreciation	7,311,589	(60,249,806)
CHANGE IN NET ASSETS RESULTING FROM OPERATIONS	10,663,027	(61,965,231)
Distributions to Shareholders:		
Primary Shares		(5,000,707)
Service Shares		(15,209,394)
CHANGE IN NET ASSETS RESULTING FROM DISTRIBUTIONS TO SHAREHOLDERS	_	(20,210,101)
Share Transactions:		
Proceeds from sale of shares	3,513,275	30,701,378
Net asset value of shares issued to shareholders in payment of distributions declared		20,210,085
Cost of shares redeemed	(13,139,581)	(31,674,352)
CHANGE IN NET ASSETS RESULTING FROM SHARE TRANSACTIONS	(9,626,306)	19,237,111
Change in net assets	1,036,721	(62,938,221)
Net Assets:		
Beginning of period	143,410,499	206,348,720
End of period	\$144,447,220	\$143,410,499

Notes to Financial Statements

June 30, 2023 (unaudited)

1. ORGANIZATION

Federated Hermes Insurance Series (the "Trust") is registered under the Investment Company Act of 1940, as amended (the "Act"), as an open-end management investment company. The Trust consists of six portfolios. The financial statements included herein are only those of Federated Hermes Kaufmann Fund II (the "Fund"), a diversified portfolio. The financial statements of the other portfolios are presented separately. The assets of each portfolio are segregated and a shareholder's interest is limited to the portfolio in which shares are held. Each portfolio pays its own expenses. The Fund offers two classes of shares: Primary Shares and Service Shares. All shares of the Fund have equal rights with respect to voting, except on class-specific matters. Fund shares are available exclusively as a funding vehicle for life insurance companies writing variable life insurance policies and variable annuity contracts. The investment objective of the Fund is capital appreciation.

2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Fund in the preparation of its financial statements. These policies are in conformity with U.S. generally accepted accounting principles (GAAP).

Investment Valuation

In calculating its net asset value (NAV), the Fund generally values investments as follows:

- Equity securities listed on an exchange or traded through a regulated market system are valued at their last reported sale price or official closing price in their principal exchange or market.
- Fixed-income securities are fair valued using price evaluations provided by a pricing service approved by Federated Equity Management Company of Pennsylvania (the "Adviser").
- Shares of other mutual funds or non-exchange-traded investment companies are valued based upon their reported NAVs, or NAV per share practical expedient, as applicable.
- Derivative contracts listed on exchanges are valued at their reported settlement or closing price, except that options are valued at the mean of closing bid and ask quotations.
- Over-the-counter (OTC) derivative contracts are fair valued using price evaluations provided by a pricing service approved by the Adviser.
- For securities that are fair valued in accordance with procedures established by and under the general supervision of the Adviser, certain factors may be considered, such as: the last traded or purchase price of the security, information obtained by contacting the issuer or dealers, analysis of the issuer's financial statements or other available documents, fundamental analytical data, the nature and duration of restrictions on disposition, the movement of the market in which the security is normally traded, public trading in similar securities or derivative contracts of the issuer or comparable issuers, movement of a relevant index, or other factors including but not limited to industry changes and relevant government actions.

If any price, quotation, price evaluation or other pricing source is not readily available when the NAV is calculated, if the Fund cannot obtain price evaluations from a pricing service or from more than one dealer for an investment within a reasonable period of time as set forth in the Adviser's valuation policies and procedures for the Fund, or if information furnished by a pricing service, in the opinion of the Adviser's valuation committee ("Valuation Committee"), is deemed not representative of the fair value of such security, the Fund uses the fair value of the investment determined in accordance with the procedures described below. There can be no assurance that the Fund could obtain the fair value assigned to an investment if it sold the investment at approximately the time at which the Fund determines its NAV per share, and the actual value obtained could be materially different.

Fair Valuation and Significant Events Procedures

Pursuant to Rule 2a-5 under the Act, the Fund's Board of Trustees (the "Trustees") has designated the Adviser as the Fund's valuation designee to perform any fair value determinations for securities and other assets held by the Fund. The Adviser is subject to the Trustees' oversight and certain reporting and other requirements intended to provide the Trustees the information needed to oversee the Adviser's fair value determinations.

The Adviser, acting through its Valuation Committee, is responsible for determining the fair value of investments for which market quotations are not readily available. The Valuation Committee is comprised of officers of the Adviser and certain of the Adviser's affiliated companies and determines fair value and oversees the calculation of the NAV. The Valuation Committee is also authorized to use pricing services to provide fair value evaluations of the current value of certain investments for purposes of calculating the NAV. The Valuation Committee employs various methods for reviewing third-party pricing-service evaluations including periodic reviews of third-party pricing services' policies, procedures and valuation methods (including key inputs, methods, models and assumptions), transactional back-testing, comparisons of evaluations of different pricing services, and review of price challenges by the Adviser based on recent market activity. In the event that market quotations and price evaluations are not available for an investment, the Valuation Committee determines the fair value of the investment in accordance with procedures adopted by the Adviser. The Trustees periodically review the fair valuations made by the Valuation Committee. The Trustees have also approved the Adviser's fair valuation and significant events procedures as part of the Fund's compliance program and will review any changes made to the procedures.

Factors considered by pricing services in evaluating an investment include the yields or prices of investments of comparable quality, coupon, maturity, call rights and other potential prepayments, terms and type, reported transactions, indications as to values from dealers and general market conditions. Some pricing services provide a single price evaluation reflecting the bid-side of the market for an investment (a "bid" evaluation). Other pricing services offer both bid evaluations and price evaluations indicative of a price between

the prices bid and ask for the investment (a "mid" evaluation). The Fund normally uses bid evaluations for any U.S. Treasury and Agency securities, mortgage-backed securities and municipal securities. The Fund normally uses mid evaluations for any other types of fixed-income securities and any OTC derivative contracts. In the event that market quotations and price evaluations are not available for an investment, the fair value of the investment is determined in accordance with procedures adopted by the Adviser.

The Adviser has also adopted procedures requiring an investment to be priced at its fair value whenever the Valuation Committee determines that a significant event affecting the value of the investment has occurred between the time as of which the price of the investment would otherwise be determined and the time as of which the NAV is computed. An event is considered significant if there is both an affirmative expectation that the investment's value will change in response to the event and a reasonable basis for quantifying the resulting change in value. Examples of significant events that may occur after the close of the principal market on which a security is traded, or after the time of a price evaluation provided by a pricing service or a dealer, include:

- With respect to securities traded principally in foreign markets, significant trends in U.S. equity markets or in the trading of foreign securities index futures contracts;
- Political or other developments affecting the economy or markets in which an issuer conducts its operations or its securities are traded;
- Announcements concerning matters such as acquisitions, recapitalizations, litigation developments, or a natural disaster affecting the issuer's operations or regulatory changes or market developments affecting the issuer's industry.

The Adviser has adopted procedures whereby the Valuation Committee uses a pricing service to provide factors to update the fair value of equity securities traded principally in foreign markets from the time of the close of their respective foreign stock exchanges to the pricing time of the Fund. For other significant events, the Fund may seek to obtain more current quotations or price evaluations from alternative pricing sources. If a reliable alternative pricing source is not available, the Valuation Committee will determine the fair value of the investment in accordance with the fair valuation procedures approved by the Adviser. The Trustees periodically review fair valuations made in response to significant events.

Repurchase Agreements

The Fund may invest in repurchase agreements for short-term liquidity purposes. It is the policy of the Fund to require the other party to a repurchase agreement to transfer to the Fund's custodian or sub-custodian eligible securities or cash with a market value (after transaction costs) at least equal to the repurchase price to be paid under the repurchase agreement. The eligible securities are transferred to accounts with the custodian or sub-custodian in which the Fund holds a "securities entitlement" and exercises "control" as those terms are defined in the Uniform Commercial Code. The Fund has established procedures for monitoring the market value of the transferred securities and requiring the transfer of additional eligible securities if necessary to equal at least the repurchase price. These procedures also allow the other party to require securities to be transferred from the account to the extent that their market value exceeds the repurchase price or in exchange for other eligible securities of equivalent market value.

The insolvency of the other party or other failure to repurchase the securities may delay the disposition of the underlying securities or cause the Fund to receive less than the full repurchase price. Under the terms of the repurchase agreement, any amounts received by the Fund in excess of the repurchase price and related transaction costs must be remitted to the other party.

The Fund may enter into repurchase agreements in which eligible securities are transferred into joint trading accounts maintained by the custodian or sub-custodian for investment companies and other clients advised by the Fund's Adviser and its affiliates. The Fund will participate on a pro rata basis with the other investment companies and clients in its share of the securities transferred under such repurchase agreements and in its share of proceeds from any repurchase or other disposition of such securities.

Repurchase agreements are subject to Master Netting Agreements (MNA) which are agreements between the Fund and its counterparties that provide for the net settlement of all transactions and collateral with the Fund, through a single payment, in the event of default or termination. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated above, the cash or securities to be repurchased, as shown on the Portfolio of Investments, exceeds the repurchase price to be paid under the agreement reducing the net settlement amount to zero.

Investment Income, Gains and Losses, Expenses and Distributions

Investment transactions are accounted for on a trade-date basis. Realized gains and losses from investment transactions are recorded on an identified-cost basis. Interest income and expenses are accrued daily. Dividend income and distributions to shareholders are recorded on the ex-dividend date. Foreign dividends are recorded on the ex-dividend date or when the Fund is informed of the ex-dividend date. Amortization/accretion of premium and discount is included in investment income. Distributions of net investment income, if any, are declared and paid annually. Non-cash dividends included in dividend income, if any, are recorded at fair value. Investment income, realized and unrealized gains and losses, and certain fund-level expenses are allocated to each class based on relative average daily net assets, except that select classes will bear certain expenses unique to those classes. Dividends are declared separately for each class. No class has preferential dividend rights; differences in per share dividend rates are generally due to differences in separate class expenses.

Federal Taxes

It is the Fund's policy to comply with the Subchapter M provision of the Internal Revenue Code of 1986 (the "Code") and to distribute to shareholders each year substantially all of its income. Accordingly, no provision for federal income tax is necessary. As of and during the six months ended June 30, 2023, the Fund did not have a liability for any uncertain tax positions. The Fund recognizes interest and penalties, if any, related to tax liabilities as income tax expense in the Statement of Operations. As of June 30, 2023, tax years 2019 through 2022 remain subject to examination by the Fund's major tax jurisdictions, which include the United States of America and the Commonwealth of Massachusetts.

The Fund may be subject to taxes imposed by governments of countries in which it invests. Such taxes are generally based on either income or gains earned or repatriated. The Fund accrues and applies such taxes to net investment income, net realized gains and net unrealized gains as income and/or gains are earned.

When-Issued and Delayed-Delivery Transactions

The Fund may engage in when-issued or delayed-delivery transactions. The Fund records when-issued securities on the trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked to market daily and begin earning interest on the settlement date. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

Futures Contracts

The Fund purchases and sells financial futures contracts to manage currency risk and market risks. Upon entering into a financial futures contract with a broker, the Fund is required to deposit with a broker, either U.S. government securities or a specified amount of cash, which is shown as due from broker in the Statement of Assets and Liabilities. Futures contracts are valued daily and unrealized gains or losses are recorded in a "variation margin" account. The Fund receives from or pays to the broker a specified amount of cash based upon changes in the variation margin account. When a contract is closed, the Fund recognizes a realized gain or loss. Futures contracts have market risks, including the risk that the change in the value of the contract may not correlate with the changes in the value of the underlying securities. There is minimal counterparty risk to the Fund since futures contracts are exchange traded and the exchange's clearinghouse, as counterparty to all exchange-traded futures contracts, guarantees the futures contracts against default.

During the six months ended June 30, 2023, the Fund held no futures contracts.

Foreign Exchange Contracts

The Fund enters into foreign exchange contracts for the delayed-delivery of securities or foreign currency exchange transactions. The Fund also enters into foreign exchange contracts to protect assets against adverse changes in foreign currency exchange rates or exchange control regulations. Purchased contracts are used to acquire exposure to foreign currencies, whereas, contracts to sell are used to hedge the Fund's securities against currency fluctuations. Risks may arise upon entering into these transactions from the potential inability of counterparties to meet the terms of their commitments and from unanticipated movements in security prices or foreign exchange contracts are adjusted by the daily exchange rate of the underlying currency and any gains or losses are recorded for financial statement purposes as unrealized until the settlement date.

During the six months ended June 30, 2023, the Fund held no foreign exchange contracts.

Foreign Currency Translation

The accounting records of the Fund are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rates of exchange of such currencies against U.S. dollars on the date of valuation. Purchases and sales of securities, income and expenses are translated at the rate of exchange quoted on the respective date that such transactions are recorded. The Fund does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations are included with the net realized and unrealized gain or loss from investments.

Reported net realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized between the trade and settlement dates on securities transactions, the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books, and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities other than investments in securities at period end, resulting from changes in the exchange rate.

Securities Lending

The Fund participates in a securities lending program providing for the lending of equity securities to qualified brokers. The term of the loans within the program is one year or less. The Fund normally receives cash collateral for securities loaned that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements. Investments in money market funds may include funds with a "floating" NAV that can impose redemption fees and liquidity gates, impose certain operational impediments to investing cash collateral, and, if the investee fund's NAV decreases, result in the Fund recognizing losses and being required to cover the decrease in the value of the cash collateral. Collateral is maintained at a minimum level of 100% of the market value of investments loaned, plus interest, if applicable. In accordance with the Fund's securities lending agreement, the market value of securities on loan is determined each day at the close of business and any additional collateral required to cover the value of securities lending agent, as a fee for its services under the program and the Fund, according to agreed-upon rates. The Fund will not have the right to vote on securities while they are on loan. However, the Fund will attempt to terminate a loan in an effort to reacquire the securities in time to vote on matters that are deemed to be material by the Adviser. There can be no assurance that the Fund will have sufficient notice of such matters to be able to terminate the loan in time to vote thereon.

Securities lending transactions are subject to MNA. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated below, the cash collateral received by the Fund exceeds the market value of the securities loaned reducing the net settlement amount to zero. The chart below identifies the amount of collateral received as well as the market value of securities on loan. Additionally, the securities lending agreement executed by the Fund includes an indemnification clause. This clause stipulates that the borrower will reimburse the Fund for any losses as a result of any failure of the borrower to return equivalent securities to the Fund.

As of June 30, 2023, securities subject to this type of arrangement and related collateral were as follows:

Fair Value of	Collateral
Securities Loaned	Received
\$1,846,074	\$1,877,119

Restricted Securities

The Fund may purchase securities which are considered restricted. Restricted securities are securities that either: (a) cannot be offered for public sale without first being registered, or being able to take advantage of an exemption from registration, under the Securities Act of 1933; or (b) are subject to contractual restrictions on public sales. In some cases, when a security cannot be offered for public sale without first being registered, the issuer of the restricted security has agreed to register such securities for resale, at the issuer's expense, either upon demand by the Fund or in connection with another registered offering of the securities. Many such restricted securities may be resold in the secondary market in transactions exempt from registration. Restricted securities may be determined to be liquid under criteria established by the Trustees. The Fund will not incur any registration costs upon such resales. The Fund's restricted securities, like other securities, are priced in accordance with procedures established by and under the general supervision of the Adviser.

Other

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, expenses and revenues reported in the financial statements. Actual results could differ materially from those estimated. The Fund applies investment company accounting and reporting guidance.

3. SHARES OF BENEFICIAL INTEREST

The following tables summarize share activity:

		Six Months Ended 6/30/2023		Year Ended 12/31/2022	
Primary Shares:	Shares	Amount	Shares	Amount	
Shares sold	23,036	\$ 358,979	126,871	\$ 2,146,304	
Shares issued to shareholders in payment of distributions declared		_	277,971	5,000,705	
Shares redeemed	(216,287)	(3,381,725)	(402,248)	(6,715,513)	
NET CHANGE RESULTING FROM PRIMARY SHARE TRANSACTIONS	(193,251)	\$(3,022,746)	2,594	\$ 431,496	

		Six Months Ended 6/30/2023		Year Ended 12/31/2022	
Service Shares:	Shares	Amount	Shares	Amount	
Shares sold	223,574	\$ 3,154,296	1,893,686	\$ 28,555,074	
Shares issued to shareholders in payment of distributions declared	_	_	928,534	15,209,380	
Shares redeemed	(687,202)	(9,757,856)	(1,623,969)	(24,958,839)	
NET CHANGE RESULTING FROM SERVICE SHARE TRANSACTIONS	(463,628)	\$(6,603,560)	1,198,251	\$ 18,805,615	
NET CHANGE RESULTING FROM TOTAL FUND SHARE TRANSACTIONS	(656,879)	\$(9,626,306)	1,200,845	\$ 19,237,111	

4. FEDERAL TAX INFORMATION

At June 30, 2023, the cost of investments for federal tax purposes was \$103,227,745. The net unrealized appreciation of investments for federal tax purposes was \$43,097,516. This consists of unrealized appreciation from investments for those securities having an excess of value over cost of \$49,222,688 and unrealized depreciation from investments for those securities having an excess of cost over value of \$6,125,172.

As of December 31, 2022, the Fund had a capital loss carryforward of \$721,039 which will reduce the Fund's taxable income arising from future net realized gains on investments, if any, to the extent permitted by the Code, thereby reducing the amount of distributions to shareholders which would otherwise be necessary to relieve the Fund of any liability for federal income tax. Pursuant to the Code, these net capital losses retain their character as either short-term or long-term and do not expire.

The following schedule summarizes the Fund's capital loss carryforwards:

Short-Term	Long-Term	Total
\$721,039	\$—	\$721,039

5. INVESTMENT ADVISER FEE AND OTHER TRANSACTIONS WITH AFFILIATES

Investment Adviser Fee

The advisory agreement between the Fund and the Adviser provides for an annual fee equal to 1.30% of the Fund's average daily net assets. The Adviser may voluntarily choose to waive any portion of its fee and/or reimburse certain operating expenses of the Fund for competitive reasons such as to maintain the Fund's expense ratio, or as and when appropriate, to maintain positive or zero net yields. For the six months ended June 30, 2023, the Adviser did not voluntarily waive any of its fee.

Certain of the Fund's assets are managed by Federated Global Investment Management Corp. (the "Sub-Adviser"). Under the terms of a sub-advisory agreement between the Adviser and the Sub-Adviser, the Sub-Adviser receives an allocable portion of the Fund's adviser fee. The fee is paid by the Adviser out of its resources and is not an incremental Fund expense. For the six months ended June 30, 2023, the Sub-Adviser earned a fee of \$757,288.

Administrative Fee

Federated Administrative Services (FAS), under the Administrative Services Agreement, provides the Fund with administrative personnel and services. For purposes of determining the appropriate rate breakpoint, "Investment Complex" is defined as all of the Federated Hermes Funds subject to a fee under the Administrative Services Agreement. The fee paid to FAS is based on the average daily net assets of the Investment Complex as specified below:

Administrative Fee	Average Daily Net Assets of the Investment Complex
0.100%	on assets up to \$50 billion
0.075%	on assets over \$50 billion

FAS may voluntarily choose to waive any portion of its fee. For the six months ended June 30, 2023, the annualized fee paid to FAS was 0.080% of average daily net assets of the Fund.

In addition, FAS may charge certain out-of-pocket expenses to the Fund.

Distribution Services Fee

The Fund has adopted a Distribution Plan (the "Plan") pursuant to Rule 12b-1 under the Act. Under the terms of the Plan, the Fund will compensate Federated Securities Corp. (FSC), the principal distributor, from the daily net assets of the Fund's Primary Shares and Service Shares to finance activities intended to result in the sale of these shares. The Plan provides that the Fund may incur distribution expenses at the following percentages of average daily net assets annually, to compensate FSC:

	Percentage of Average Daily Net Assets of Class
Primary Shares	0.25%
Service Shares	0.25%

FSC may voluntarily choose to waive any portion of its fee. For the six months ended June 30, 2023, distribution services fees for the Fund were as follows:

	Distribution Services Fees Incurred
Service Shares	\$135,280

When FSC receives fees, it may pay some or all of them to financial intermediaries whose customers purchase shares. For the six months ended June 30, 2023, the Fund's Primary Shares did not incur a distribution services fee; however, it may begin to incur this fee upon approval of the Trustees.

Interfund Transactions

During the six months ended June 30, 2023, the Fund engaged in purchase and sale transactions with funds that have a common investment adviser (or affiliated investment advisers), common Directors/Trustees and/or common Officers. These purchase and sale transactions complied with Rule 17a-7 under the Act and amounted to \$191,681 and \$136,684, respectively. Net realized gain recognized on these transactions was \$45,943.

Directors'/Trustees' and Miscellaneous Fees

Certain Officers and Trustees of the Fund are Officers and Directors or Trustees of certain of the above companies. To efficiently facilitate payment, Independent Directors'/Trustees' fees and certain expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses are paid by an affiliate of the Adviser which in due course are reimbursed by the Fund. These expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses may be included in Accrued and Miscellaneous Expenses on the Statement of Assets and Liabilities and Statement of Operations, respectively.

6. INVESTMENT TRANSACTIONS

Purchases and sales of investments, excluding long-term U.S. government securities and short-term obligations, for the six months ended June 30, 2023, were as follows:

Purchases	\$40,166,010
Sales	\$30,729,033

7. CONCENTRATION OF RISK

The Fund may invest a portion of its assets in securities of companies that are deemed by the Fund's management to be classified in similar business sectors. Economic developments may have an effect on the liquidity and volatility of the portfolio securities. A substantial portion of the Fund's portfolio may be comprised of entities in the Health Care sector. As a result, the Fund may be more susceptible to any economic, business, political or other developments which generally affect these entities.

8. LINE OF CREDIT

The Fund participates with certain other Federated Hermes Funds, on a several basis, in an up to \$500,000,000 unsecured, 364-day, committed, revolving line of credit (LOC) agreement dated June 21, 2023. The LOC was made available to temporarily finance the repurchase or redemption of shares of the Fund, failed trades, payment of dividends, settlement of trades and for other short-term, temporary or emergency general business purposes. The Fund cannot borrow under the LOC if an inter-fund loan is outstanding. The Fund's ability to borrow under the LOC also is subject to the limitations of the Act and various conditions precedent that must be satisfied before the Fund can borrow. Loans under the LOC are charged interest at a fluctuating rate per annum equal to (a) the highest, on any day, of (i) the federal funds effective rate, (ii) the published secured overnight financing rate plus an assigned percentage, and (iii) 0.0%, plus (b) a margin. Any fund eligible to borrow under the LOC pays its pro rata share of a commitment fee based on the amount of the lenders' commitment that has not been utilized, quarterly in arrears and at maturity. As of June 30, 2023, the Fund had no outstanding loans. During the six months ended June 30, 2023, the Fund did not utilize the LOC.

9. INTERFUND LENDING

Pursuant to an Exemptive Order issued by the Securities and Exchange Commission, the Fund, along with other funds advised by subsidiaries of Federated Hermes, Inc., may participate in an interfund lending program. This program provides an alternative credit facility allowing the Fund to borrow from other participating affiliated funds. As of June 30, 2023, there were no outstanding loans. During the six months ended June 30, 2023, the program was not utilized.

10. INDEMNIFICATIONS

Under the Fund's organizational documents, its Officers and Directors/Trustees are indemnified against certain liabilities arising out of the performance of their duties to the Fund (other than liabilities arising out of their willful misfeasance, bad faith, gross negligence or reckless disregard of their duties to the Fund). In addition, in the normal course of business, the Fund provides certain indemnifications under arrangements with third parties. Typically, obligations to indemnify a third party arise in the context of an arrangement entered into by the Fund under which the Fund agrees to indemnify such third party for certain liabilities arising out of actions taken pursuant to the arrangement, provided the third party's actions are not deemed to have breached an agreed-upon standard of care (such as willful misfeasance, bad faith, gross negligence or reckless disregard of their duties under the contract). The Fund's maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Fund that have not yet arisen. The Fund does not anticipate any material claims or losses pursuant to these arrangements at this time, and accordingly expects the risk of loss to be remote.

11. OTHER MATTERS

An outbreak of respiratory disease caused by a novel coronavirus was first detected in China in late 2019 and subsequently spread globally. As of the date of the issuance of these financial statements, this coronavirus has resulted in, and may continue to result in, closed borders, enhanced health screenings, disruptions to healthcare service preparation and delivery, quarantines, cancellations, and disruptions to supply chains, workflow operations and consumer activity, as well as general concern and uncertainty. The impact of this coronavirus has resulted in substantial economic volatility. Health crises caused by outbreaks, such as the coronavirus outbreak, may exacerbate other pre-existing political, social and economic risks. The impact of this outbreak, and other epidemics and pandemics that may arise in the future, could continue to negatively affect the worldwide economy, as well as the economies of individual countries, individual companies (including certain Fund service providers and issuers of the Fund's investments) and the markets in general in significant and unforeseen ways. In addition, governments, their regulatory agencies, or self-regulatory organizations may take actions in response to the pandemic, including significant fiscal and monetary policy changes, that may affect the instruments in which the Fund invests or the issuers of such investments. Any such impact could adversely affect the Fund's performance.

Shareholder Expense Example (unaudited)

As a shareholder of the Fund, you incur ongoing costs, including management fees and to the extent applicable, distribution (12b-1) fees and/or other service fees and other Fund expenses. This Example is intended to help you to understand your ongoing costs (in dollars) of investing in the Fund and to compare these costs with the ongoing costs of investing in other funds used as variable investment options. It is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period from January 1, 2023 to June 30, 2023.

ACTUAL EXPENSES

The first section of the table below provides information about actual account values and actual expenses. You may use the information in this section, together with the amount you invested, to *estimate* the expenses that you incurred over the period. Simply divide your account value by 1,000 (for example, an 8,600 account value divided by 1,000 = 8.6), then multiply the result by the number in the first section under the heading entitled "Expenses Paid During Period" to estimate the expenses attributable to your investment during this period.

HYPOTHETICAL EXAMPLE FOR COMPARISON PURPOSES

The second section of the table below provides information about hypothetical account values and hypothetical expenses based on the Fund's actual expense ratio and an *assumed* rate of return of 5% per year before expenses, which is not the Fund's actual return. Thus, you should *not* use the hypothetical account values and expenses to estimate the actual ending account balance or your expenses for the period. Rather, these figures are required to be provided to enable you to compare the ongoing costs of investing in the Fund with other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only. Therefore, the second section of the table is useful in comparing ongoing costs only, and will not help you determine the relative *total* costs of owning different funds.

	Beginning Account Value 1/1/2023	Ending Account Value 6/30/2023	Expenses Paid During Period
Actual:			
Primary Shares	\$1,000	\$1,078.10	\$7.93
Service Shares	\$1,000	\$1,076.50	\$9.22
Hypothetical (assuming a 5% return before expenses):			
Primary Shares	\$1,000	\$1,017.16	\$7.70
Service Shares	\$1,000	\$1,015.92	\$8.95

1 Expenses are equal to the Fund's annualized net expense ratios, multiplied by the average account value over the period, multiplied by 181/365 (to reflect the one-half-year period). The expenses shown in the table do not include the charges and expenses imposed by the insurance company under the variable insurance product contract. Please refer to the variable insurance product prospectus for a complete listing of these expenses. The annualized net expense ratios are as follows:

Primary Shares	1.54%
Service Shares	1.79%

Evaluation and Approval of Advisory Contract-May 2023

FEDERATED HERMES KAUFMANN FUND II (THE "FUND")

At its meetings in May 2023 (the "May Meetings"), the Fund's Board of Trustees (the "Board"), including those Trustees who are not "interested persons" of the Fund, as defined in the Investment Company Act of 1940 (the "Independent Trustees"), reviewed and unanimously approved the continuation of the investment advisory contract between the Fund and Federated Equity Management Company of Pennsylvania (the "Adviser") and the investment subadvisory contract between the Adviser and Federated Global Investment Management Corp. (the "Sub-Adviser" and together with the Adviser, the "Advisers") with respect to the Fund (together, the "Contracts") for an additional one-year term. The Board's determination to approve the continuation of the Contracts reflects the exercise of its business judgment after considering all of the information and factors believed to be relevant and appropriate on whether to approve the continuation of the existing arrangements. The information, factors and conclusions that formed the basis for the Board's approval are summarized below.

Information Received and Review Process

At the request of the Independent Trustees, the Fund's Chief Compliance Officer (the "CCO") furnished to the Board in advance of its May Meetings an independent written evaluation of the Fund's management fee (the "CCO Fee Evaluation Report"). The Board considered the CCO Fee Evaluation Report, along with other information, in evaluating the reasonableness of the Fund's management fee and in determining to approve the continuation of the Contracts. The CCO, in preparing the CCO Fee Evaluation Report, has the authority to retain consultants, experts or staff as reasonably necessary to assist in the performance of his duties, reports directly to the Board, and can be terminated only with the approval of a majority of the Independent Trustees. At the request of the Independent Trustees, the CCO Fee Evaluation Report followed the same general approach and covered the same topics as that of the report that had previously been delivered by the CCO in his capacity as "Senior Officer" prior to the elimination of the Senior Officer position in December 2017.

In addition to the extensive materials that comprise and accompany the CCO Fee Evaluation Report, the Board considered information specifically prepared in connection with the approval of the continuation of the Contracts that was presented at the May Meetings. In this regard, in the months preceding the May Meetings, the Board requested and reviewed written responses and supporting materials prepared by the Advisers and their affiliates (collectively, "Federated Hermes") in response to requests posed to Federated Hermes by independent legal counsel on behalf of the Independent Trustees encompassing a wide variety of topics, including those summarized below. The Board also considered such additional matters as the Independent Trustees deemed reasonably necessary to evaluate the Contracts, which included detailed information about the Fund and Federated Hermes furnished to the Board at its meetings throughout the year and in between regularly scheduled meetings on particular matters as the need arose. The Independent Trustees also considered at the presentation from the Fund's portfolio managers received at the May Meetings regarding the Fund and its performance and other investment-related matters.

The Board's consideration of the Contracts included review of materials and information covering the following matters, among others: the nature, quality and extent of the advisory and other services provided to the Fund by Federated Hermes; Federated Hermes' business and operations; the Advisers' investment philosophy, personnel and processes; the Fund's investment objectives and strategies; the Fund's short-term and long-term performance (in absolute terms, both on a gross basis and net of expenses, and relative to the Fund's particular investment program and a group of its peer funds and/or its benchmark, as appropriate); the Fund's fees and expenses, including the advisory fee and the overall expense structure of the Fund (both in absolute terms and relative to a group of its peer funds), with due regard for contractual or voluntary expense limitations (if any); the financial condition of Federated Hermes; the Adviser's profitability with respect to managing the Fund; distribution and sales activity for the Fund; and the use and allocation of brokerage commissions derived from trading the Fund's portfolio securities (if any).

The Board also considered judicial decisions concerning allegedly excessive investment advisory fees charged to other registered funds in evaluating the Contracts. Using these judicial decisions as a guide, the Board observed that the following factors may be relevant to an adviser's fiduciary duty with respect to its receipt of compensation from a fund: (1) the nature and quality of the services provided by the adviser to the fund and its shareholders, including the performance of the fund, its benchmark and comparable funds; (2) the adviser's cost of providing the services and the profitability to the adviser of providing advisory services to the fund; (3) the extent to which the adviser may realize "economies of scale" as the fund grows larger and, if such economies of scale exist, whether they have been appropriately shared with the fund and its shareholders or the family of funds; (4) any "fall-out" benefits that accrue to the adviser because of its relationship with the fund, including research services received from brokers that execute fund trades and any fees paid to affiliates of the adviser for services rendered to the fund; (5) comparative fee and expense structures, including a comparison of management fees paid to the adviser with those paid by similar funds managed by the same

adviser or other advisers as well as management fees charged to institutional and other advisory clients of the same adviser for what might be viewed as like services; and (6) the extent of care, conscientiousness and independence with which the fund's board members perform their duties and their expertise, including whether they are fully informed about all facts the board deems relevant to its consideration of the adviser's services and fees. The Board noted that the Securities and Exchange Commission ("SEC") disclosure requirements regarding the basis for a fund board's approval of the fund's investment advisory contract generally align with the factors listed above. The Board was guided by these factors in its evaluation of the Contracts to the extent it considered them to be appropriate and relevant, as discussed further below. The Board considered and weighed these factors in light of its substantial accumulated experience in governing the Fund and working with Federated Hermes on matters relating to the oversight of the other funds advised by Federated Hermes (each, a "Federated Hermes Fund" and, collectively, the "Federated Hermes Funds").

In addition, the Board considered the preferences and expectations of Fund shareholders and the potential disruptions of the Fund's operations and various risks, uncertainties and other effects that could occur as a result of a decision to terminate or not renew the Contracts. In particular, the Board recognized that many shareholders likely have invested in the Fund based on the strength of Federated Hermes' industry standing and reputation and with the expectation that Federated Hermes will have a continuing role in providing advisory services to the Fund. Thus, the Board observed that there are a range of investment options available to the Fund's shareholders in the marketplace, and such shareholders, having had the opportunity to consider other investment options, have effectively selected Federated Hermes by virtue of investing in the Fund.

In determining to approve the continuation of the Contracts, the members of the Board reviewed and evaluated information and factors they believed to be relevant and appropriate through the exercise of their reasonable business judgment. While individual members of the Board may have weighed certain factors differently, the Board's determination to approve the continuation of the Contracts was based on a comprehensive consideration of all information provided to the Board throughout the year and specifically with respect to the continuation of the Contracts. The Board recognized that its evaluation process is evolutionary and that the factors considered and emphasis placed on relevant factors may change in recognition of changing circumstances in the registered fund marketplace. The Independent Trustees were assisted throughout the evaluation process by independent legal counsel. In connection with their deliberations at the May Meetings, the Independent Trustees met separately in executive session with their independent legal counsel and without management present to review the relevant materials and consider their responsibilities under applicable laws. In addition, senior management representatives of Federated Hermes also met with the Independent Trustees and their independent legal counsel to discuss the materials and presentations furnished to the Board at the May Meetings. The Board considered the approval of the Contracts for the Fund as part of its consideration of agreements for funds across the family of Federated Hermes Funds, but its approvals were made on a fund-by-fund basis.

Nature, Extent and Quality of Services

The Board considered the nature, extent and quality of the services provided to the Fund by the Advisers and the resources of Federated Hermes dedicated to the Fund. In this regard, the Board evaluated, among other things, the terms of the Contracts and the range of services provided to the Fund by Federated Hermes. The Board considered the Advisers' personnel, investment philosophy and process, investment research capabilities and resources, trade operations capabilities, experience and performance track record. The Board reviewed the qualifications, backgrounds and responsibilities of the portfolio management team primarily responsible for the day-to-day management of the Fund and Federated Hermes' ability and experience in attracting and retaining qualified personnel to service the Fund. The Board considered the trading operations by the Advisers, including the execution of portfolio transactions and the selection of brokers for those transactions. The Board also considered the Advisers' ability to deliver competitive investment performance for the Fund when compared to the Fund's Performance Peer Group (as defined below), which was deemed by the Board to be a useful indicator of how the Advisers are executing the Fund's investment program.

In addition, the Board considered the financial resources and overall reputation of Federated Hermes and its willingness to consider and make investments in personnel, infrastructure, technology, cybersecurity, business continuity planning and operational enhancements that are designed to benefit the Federated Hermes Funds. The Board noted that the significant acquisition of Hermes Fund Managers Limited by Federated Hermes has deepened Federated Hermes' investment management expertise and capabilities and expanded its access to analytical resources related to environmental, social and governance ("ESG") factors and issuer engagement on ESG matters. The Board considered Federated Hermes' oversight of the securities lending program for the Federated Hermes Funds that engage in securities lending and noted the income earned by the Federated Hermes Funds that participate in such program. In addition, the Board considered the quality of Federated Hermes' communications with the Board and responsiveness to Board inquiries and requests made from time to time with respect to the Federated Hermes Funds. The Board also considered that Federated Hermes is responsible for providing the Federated Hermes Funds' officers.

The Board received and evaluated information regarding Federated Hermes' regulatory and compliance environment. The Board considered Federated Hermes' compliance program and compliance history and reports from the CCO about Federated Hermes' compliance with applicable laws and regulations, including responses to regulatory developments and any compliance or other issues raised by regulatory agencies. The Board also noted Federated Hermes' support of the Federated Hermes Funds' compliance control structure and the compliance-related resources devoted by Federated Hermes in support of the Fund's obligations pursuant to Rule 38a-1 under the Investment Company Act of 1940, including Federated Hermes' commitment to respond to rulemaking and other regulatory initiatives of the SEC. The Board considered Federated Hermes' approach to risk management with respect to the Federated Hermes Funds and its day-to-day oversight of the Federated Hermes' oversight in this regard, including in connection with the implementation of new rules on derivatives risk management and fair valuation. The Board also considered the implementation of Federated Hermes' business continuity plans. In addition, the Board noted Federated Hermes' commitment to maintaining high quality systems and expending substantial resources to prepare for and respond to ongoing changes due to the market, regulatory and control environments in which the Fund and its service providers operate.

The Board considered Federated Hermes' efforts to provide shareholders in the Federated Hermes Funds with a comprehensive array of funds with different investment objectives, policies and strategies. The Board considered the expenses that Federated Hermes had incurred, as well as the entrepreneurial and other risks assumed by Federated Hermes, in sponsoring and providing on-going services to new funds to expand these opportunities for shareholders. The Board noted the benefits to shareholders of being part of the family of Federated Hermes Funds, which include the general right to exchange investments between the same class of shares without the incurrence of additional sales charges.

Based on these considerations, the Board concluded that it was satisfied with the nature, extent and quality of the services provided by the Advisers to the Fund.

Fund Investment Performance

The Board considered the investment performance of the Fund. In evaluating the Fund's investment performance, the Board considered performance results in light of the Fund's investment objective, strategies and risks. The Board considered detailed investment reports on, and the Advisers' analysis of, the Fund's performance over different time periods that were provided to the Board throughout the year and in connection with the May Meetings. These reports included, among other items, information on the Fund's gross and net returns, the Fund's investment performance compared to one or more relevant categories or groups of peer funds and the Fund's benchmark index, performance attribution information and commentary on the effect of market conditions. The Board considered that, in its evaluation of investment performance at meetings throughout the year, it focused particular attention on information indicating less favorable performance of certain Federated Hermes Funds for specific time periods and discussed with Federated Hermes the reasons for such performance as well as any specific actions Federated Hermes had taken, or had agreed to take, to seek to enhance Fund investment performance and the results of those actions.

The Board also reviewed comparative information regarding the performance of other registered funds in the category of peer funds selected by Morningstar, Inc. (the "Morningstar"), an independent fund ranking organization (the "Performance Peer Group"). The Board noted the CCO's view that comparisons to fund peer groups may be helpful, though not conclusive, in evaluating the performance of the Advisers in managing the Fund. The Board considered the CCO's view that, in evaluating such comparisons, in some cases there may be differences in the funds' objectives or investment management techniques, or the costs to implement the funds, even within the same Performance Peer Group. In this connection, the Board considered that the longevity and experience of the Fund's portfolio management team and its extensive bottom-up approach to investing may limit the utility of comparisons to other equity mutual funds.

The Board considered that the Fund's performance fell below the median of the Performance Peer Group for the oneyear, three-year and five-year periods ended December 31, 2022. The Board discussed the Fund's performance with the Advisers and recognized the efforts being taken by the Advisers in the context of other factors considered relevant by the Board.

Based on these considerations, the Board concluded that it had continued confidence in the Advisers' overall capabilities to manage the Fund.

Fund Expenses

The Board considered the advisory fee, sub-advisory fee, and overall expense structure of the Fund and the comparative fee and expense information that had been provided in connection with the May Meetings. In this regard, the Board was presented with, and considered, information regarding the contractual advisory fee rates, total expense ratios and each element of the Fund's total expense ratio (i.e., gross and net advisory fees, administrative fees, custody fees, portfolio accounting fees and transfer agency fees) relative to an appropriate group of peer funds compiled by Federated Hermes

from the category of peer funds selected by Morningstar (the "Expense Peer Group"). The Board received a description of the methodology used to select the Expense Peer Group from the overall Morningstar category. The Board also reviewed comparative information regarding the fees and expenses of the broader group of funds in the overall Morningstar category.

While mindful that courts have cautioned against giving too much weight to comparative information concerning fees charged to funds by other advisers, the use of comparisons between the Fund and its Expense Peer Group assisted the Board in its evaluation of the Fund's fees and expenses. The Board focused on comparisons with other registered funds with comparable investment programs more heavily than non-registered fund products or services because such comparisons are believed to be more relevant. The Board considered that other registered funds are the products most like the Fund, in that they are readily available to Fund shareholders as alternative investment vehicles, and they are the type of investment vehicle, in fact, chosen and maintained by the Fund's shareholders. The Board noted that the range of such other registered funds' fees and expenses, therefore, appears to be a relevant indicator of what investors have found to be reasonable in the marketplace in which the Fund competes.

The Board reviewed the contractual advisory fee rate, and other expenses of the Fund and noted the position of the Fund's contractual advisory fee rate and other expenses relative to its Expense Peer Group. In this regard, the Board noted that the contractual advisory fee rate was above the median of the Expense Peer Group, but the Board noted the applicable waivers and reimbursements, and that the overall expense structure of the Fund remained competitive in the context of other factors considered by the Board.

The Board also received and considered information about the nature and extent of services offered and fees charged by Federated Hermes to other types of clients with investment strategies similar to those of the Federated Hermes Funds, including non-registered fund clients (such as institutional separate accounts) and third-party unaffiliated registered funds for which any of the Advisers or their affiliates serve as sub-adviser. The Board noted the CCO's conclusion that nonregistered fund clients are inherently different products due to the following differences, among others: (i) different types of targeted investors; (ii) different applicable laws and regulations; (iii) different legal structures; (iv) different average account sizes and portfolio management techniques made necessary by different cash flows and different associated costs; (v) the time spent by portfolio managers and their teams (among other personnel across various departments, including legal, compliance and risk management) in reviewing securities pricing and fund liquidity; (vi) different administrative responsibilities; (vii) different degrees of risk associated with management; and (viii) a variety of different costs. The Board also considered information regarding the differences in the nature of the services required for Federated Hermes to manage its proprietary registered fund business versus managing a discrete pool of assets as a sub-adviser to another institution's registered fund, noting the CCO's view that Federated Hermes generally performs significant additional services and assumes substantially greater risks in managing the Fund and other Federated Hermes Funds than in its role as sub-adviser to an unaffiliated third-party registered fund. The Board noted that the CCO did not consider the fees for providing advisory services to other types of clients to be determinative in judging the appropriateness of the Federated Hermes Funds' advisory fees.

Based on these considerations, the Board concluded that the fees and total operating expenses of the Fund, in conjunction with other matters considered, are reasonable in light of the services provided.

Profitability

The Board received and considered profitability information furnished by Federated Hermes. Such profitability information included revenues reported on a fund-by-fund basis and estimates of the allocation of expenses made on a fund-by-fund basis, using allocation methodologies specified by the CCO and described to the Board. The Board considered the CCO's view that, while these cost allocation reports apply consistent allocation processes, the inherent difficulties in allocating costs on a fund-by-fund basis continues to cause the CCO to question the precision of the process and to conclude that such reports may be unreliable because a single change in an allocation estimate may dramatically alter the resulting estimate of cost and/or profitability of a Federated Hermes Fund and may produce unintended consequences. In addition, the Board considered the CCO's view that the allocation methodologies used by Federated Hermes in estimating profitability for purposes of reporting to the Board in connection with the continuation of the Contracts are consistent with the methodologies previously reviewed by an independent consultant. The Board noted that the independent consultant had previously conducted a review of the allocation methodologies and reported to the Board that, although there is no single best method to allocate expenses, the methodologies used by Federated Hermes are reasonable.

The Board also reviewed information compiled by Federated Hermes comparing its profitability information to other publicly held fund management companies, including information regarding profitability trends over time. The Board recognized that profitability comparisons among fund management companies are difficult because of the variation in the type of comparative information that is publicly available, and the profitability of any fund management company is

affected by numerous factors. The Board considered the CCO's conclusion that, based on such profitability information, Federated Hermes' profit margins did not appear to be excessive and the advisory or administrative fees are not unreasonable. The Board also considered the CCO's view that Federated Hermes appeared financially sound, with the resources necessary to fulfill its obligations under its contracts with the Federated Hermes Funds.

Economies of Scale

The Board received and considered information about the notion of possible realization of "economies of scale" as a fund grows larger, the difficulties of determining economies of scale at an individual fund level, and the extent to which potential scale benefits are shared with shareholders. In this regard, the Board considered that Federated Hermes has made significant and long-term investments in areas that support all of the Federated Hermes Funds, such as: portfolio management, investment research and trading operations; shareholder services; compliance; business continuity, cybersecurity and information security programs; internal audit and risk management functions; and technology and use of data. The Board noted that Federated Hermes Funds and their shareholders. The Board considered that the benefits of these investments are likely to be shared with the family of Federated Hermes Funds as a whole.

In addition, the Board considered that fee waivers and expense reimbursements are another means for potential economies of scale to be shared with shareholders and can provide protection from an increase in expenses if a Federated Hermes Fund's assets decline. The Board considered that, in order for the Federated Hermes Funds to remain competitive in the marketplace, Federated Hermes has frequently waived fees and/or reimbursed expenses for the Federated Hermes Funds and has disclosed to shareholders and/or reported to the Board its intention to do so (or continue to do so) in the future. The Board also considered that Federated Hermes has been active in managing expenses of the Federated Hermes Funds in recent years, which has resulted in benefits being realized by shareholders.

The Board also received and considered information on adviser-paid fees (commonly referred to as "revenue sharing" payments) that was provided to the Board throughout the year and in connection with the May Meetings. The Board considered that Federated Hermes and the CCO believe that this information is relevant to considering whether Federated Hermes had an incentive to either not apply breakpoints, or to apply breakpoints at higher levels, but should not be considered when evaluating the reasonableness of advisory fees. The Board also noted the absence of any applicable regulatory or industry guidelines on economies of scale, which is compounded by the lack of any uniform methodology or pattern with respect to structuring fund advisory fees with breakpoints that serve to reduce the fees as a fund attains a certain size.

Other Benefits

The Board considered information regarding the compensation and other ancillary (or "fall-out") benefits that Federated Hermes derived from its relationships with the Federated Hermes Funds. The Board noted that, in addition to receiving advisory fees under the Federated Hermes Funds' investment advisory contracts, Federated Hermes' affiliates also receive fees for providing other services to the Federated Hermes Funds under separate service contracts, including for serving as the Federated Hermes Funds' administrator and distributor. In this regard, the Board considered that Federated Hermes' affiliates provide distribution and shareholder services to the Federated Hermes Funds, for which they may be compensated through distribution and servicing fees paid pursuant to Rule 12b-1 plans or otherwise. The Board also received and considered information detailing the benefits, if any, that Federated Hermes may derive from its receipt of research services from brokers who execute portfolio trades for the Federated Hermes Funds.

Conclusions

The Board considered: (i) the CCO's conclusion that his observations and the information accompanying the CCO Fee Evaluation Report show that the management fee for the Fund is reasonable; and (ii) the CCO's recommendation that the Board approve the management fee. The Board noted that, under these circumstances, no changes were recommended to, and no objection was raised to the continuation of, the Contracts by the CCO. The CCO also recognized that the Board's evaluation of the Federated Hermes Funds' advisory and sub-advisory arrangements is a continuing and ongoing process that is informed by the information that the Board requests and receives from management throughout the course of the year and, in this regard, the CCO noted certain items for future reporting to the Board or further consideration by management as the Board continues its ongoing oversight of the Federated Hermes Funds.

On the basis of the information and factors summarized above, among other information and factors deemed relevant by the Board, and the evaluation thereof, the Board, including the Independent Trustees, unanimously voted to approve the continuation of the Contracts. The Board based its determination to approve the Contracts on the totality of the circumstances and relevant factors and with a view of past and future long-term considerations. Not all of the factors and considerations identified above were necessarily deemed to be relevant to the Fund, nor did the Board consider any one of them to be determinative.

Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness

In accordance with Rule 22e-4 under the Investment Company Act of 1940, as amended (the "Liquidity Rule"), Federated Hermes Insurance Series (the "Trust") has adopted and implemented a liquidity risk management program (the "Program") for Federated Hermes Kaufmann Fund II (the "Fund" and, collectively with the other non-money market open-end funds advised by Federated Hermes, the "Federated Hermes Funds"). The Program seeks to assess and manage the Fund's liquidity risk. "Liquidity risk" is defined under the Liquidity Rule as the risk that the Fund is unable to meet redemption requests without significantly diluting remaining investors' interests in the Fund. The Board of Trustees of the Trust (the "Board") has approved the designation of each Federated Hermes Fund's investment adviser as the administrator for the Program (the "Administrator") with respect to that Fund. The Administrator, in turn, has delegated day-to-day responsibility for the administration of the Program to multiple Liquidity Risk Management Committees, which are comprised of representatives from certain divisions within Federated Hermes.

The Program is comprised of various components designed to support the assessment and/or management of liquidity risk, including: (1) the periodic assessment (no less frequently than annually) of certain factors that influence the Fund's liquidity risk; (2) the periodic classification (no less frequently than monthly) of the Fund's investments into one of four liquidity categories that reflect an estimate of their liquidity under current market conditions; (3) a 15% limit on the acquisition of "illiquid investments" (as defined under the Liquidity Rule); (4) to the extent a Fund does not invest primarily in "highly liquid investments" (as defined under the Liquidity Rule), the determination of a minimum percentage of the Fund's assets that generally will be invested in highly liquid investments (an "HLIM"); (5) if a Fund has established an HLIM, the periodic review (no less frequently than annually) of the HLIM and the adoption of policies and procedures for responding to a shortfall of the Fund's highly liquid investments below its HLIM; and (6) periodic reporting to the Board.

At its meetings in May 2023, the Board received and reviewed a written report (the "Report") from the Federated Hermes Funds' Chief Compliance Officer and Chief Risk Officer, on behalf of the Administrator, concerning the operation of the Program for the period from April 1, 2022 through March 31, 2023 (the "Period"). The Report addressed the operation of the Program and assessed the adequacy and effectiveness of its implementation, including, where applicable, the operation of any HLIM established for a Federated Hermes Fund. There were no material changes to the Program during the Period. The Report summarized the operation of the Program and factors considered by the Administrator in assessing whether the Program has been adequately and effectively implemented with respect to the Federated Hermes Funds. Such information and factors included, among other things:

- confirmation that it was not necessary for the Fund to utilize, and the Fund did not utilize, any alternative funding sources that were available to the Federated Hermes Funds during the Period, such as the Federated Hermes Funds' interfund lending facility, redemptions in-kind, reverse repurchase agreement transactions, redemptions delayed beyond the normal T+1 settlement but within seven days of the redemption request, and committed lines of credit;
- the periodic classifications of the Fund's investments into one of four liquidity categories and the methodologies and inputs used to classify the investments, including the Fund's reasonably anticipated trade size;
- the analysis received from a third-party liquidity assessment vendor that is taken into account in the process of determining the liquidity classifications of the Fund's investments, and the results of the Administrator's evaluation of the services performed by the vendor in support of this process, including the Administrator's view that the methodologies utilized by the vendor continue to be appropriate;
- the fact that the Fund invested primarily in highly liquid investments during the Period and, therefore, was not required to establish, and has not established, an HLIM and the operation of the procedures for monitoring the status of the Fund as investing primarily in highly liquid investments;
- the fact that the Fund invested no more than 15% of its assets in illiquid investments during the Period, and the operation of the procedures for monitoring this limit;
- the fact that there were no liquidity events during the Period that materially affected the Fund's liquidity risk;
- the impact on liquidity and management of liquidity risk, if any, caused by extended non-U.S. market closures and confirmation that there were no issues for any of the affected Federated Hermes Funds in meeting shareholder redemptions at any time during these temporary non-U.S. market closures.

Based on this review, the Administrator concluded that the Program is operating effectively to assess and manage the Fund's liquidity risk, and that the Program has been and continues to be adequately and effectively implemented to monitor and, as applicable, respond to the Fund's liquidity developments.

Voting Proxies on Fund Portfolio Securities

A description of the policies and procedures that the Fund uses to determine how to vote proxies, if any, relating to securities held in the Fund's portfolio is available, without charge and upon request, by calling 1-800-341-7400, Option #4. A report on "Form N-PX" of how the Fund voted any such proxies during the most recent 12-month period ended June 30 is available via the Proxy Voting Record (Form N-PX) link associated with the Fund and share class name at FederatedHermes.com/us/FundInformation. Form N-PX filings are also available at the SEC's website at sec.gov.

Quarterly Portfolio Schedule

Each fiscal quarter, the Fund will file with the SEC a complete schedule of its monthly portfolio holdings on "Form N-PORT." The Fund's holdings as of the end of the third month of every fiscal quarter, as reported on Form N-PORT, will be publicly available on the SEC's website at <u>sec.gov</u> within 60 days of the end of the fiscal quarter upon filing. You may also access this information via the link to the Fund and share class name at FederatedHermes.com/us.

Variable investment options are not bank deposits or obligations, are not guaranteed by any bank and are not insured or guaranteed by the U.S. government, the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency. Investment in variable investment options involves investment risk, including the possible loss of principal.

This Report is authorized for distribution to prospective investors only when preceded or accompanied by the Fund's Prospectus, which contains facts concerning its objective and policies, management fees, expenses and other information.

IMPORTANT NOTICE ABOUT FUND DOCUMENT DELIVERY

In an effort to reduce costs and avoid duplicate mailings, the Fund(s) intend to deliver a single copy of certain documents to each household in which more than one shareholder of the Fund(s) resides (so-called "householding"), as permitted by applicable rules. The Fund's "householding" program covers its/their Prospectus and Statement of Additional Information, and supplements to each, as well as Semi-Annual and Annual Shareholder Reports and any Proxies or information statements. Shareholders must give their written consent to participate in the "householding" program. The Fund is also permitted to treat a shareholder as having given consent ("implied consent") if (i) shareholders with the same last name, or believed to be members of the same family, reside at the same street address or receive mail at the same post office box, (ii) the Fund gives notice of its intent to "household" at least sixty (60) days before it begins "householding" and (iii) none of the shareholders who have granted written consent, or have been deemed to have granted implied consent, can revoke that consent and opt out of "householding" at any time: shareholders who purchased shares through an intermediary should contact their representative; other shareholders may call the Fund at 1-800-341-7400, Option #4.

Notes



Federated Hermes Kaufmann Fund II Federated Hermes Funds 4000 Ericsson Drive Warrendale, PA 15086-7561

Contact us at **FederatedHermes.com/us** or call 1-800-341-7400.

Federated Securities Corp., Distributor

CUSIP 313916827 CUSIP 313916777

27619 (8/23)

© 2023 Federated Hermes, Inc.